Table 1

Baseline demographic and clinical characteristics of patients (N=77)

Characteristicsn (%)
Median age at IMDC onset, years (IQR)62 (52–71)
Male51 (66)
White72 (94)
Cancer type
 Genitourinary cancer35 (44)
 Melanoma17 (22)
 Lung cancer11 (14)
 Others*14 (18)
Cancer stage
 Stage III13 (17)
 Stage IV64 (83)
Checkpoint inhibitor type
 CTLA-413 (17)
 PD-1/L137 (48)
 Combination27 (35)
Median duration from first FC test at IMDC onset to last FC test after treatment, months (IQR)9 (8–13)
Median follow-up duration, months (IQR)15 (11–26)
Death, any cause20 (26)
  • Cause of death is due to cancer progression in all 20 patients.

  • *Gastrointestinal/hepatobiliary cancer (n=5), head and neck/endocrine cancer (n=4), breast cancer (n=2), cervical cancer (n=2) and sarcoma (n=1).

  • CTLA-4, cytotoxic T lymphocyte antigen-4; FC, fecal calprotectin; IMDC, immune-mediated diarrhea and colitis; PD-1/L1, programmed death-1/programmed death-1 ligand.